Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: UBER, ZM, MSFT, STZ and CGC

Read MoreHide Full Article

For Immediate Release

Chicago, IL – April 1, 2020 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Uber (UBER - Free Report) , Zoom (ZM - Free Report) , Skype (MSFT - Free Report) , Constellation Brands (STZ - Free Report) and Canopy Growth (CGC - Free Report) .

Here are highlights from Tuesday’s Analyst Blog:

Booze Taking the Edge Off Coronavirus

The fear driving pandemic and mind-numbing quarantine has people on the brink of hysteria. Alcohol has been taking the edge off during these anxiety-ridden times. Booze sales are flying this month, and online delivery services are a primary catalyst.

Alcohol Delivery Apps

With the majority of the US stuck at home, we have never relied on technology more. Alcohol delivery apps are one such example with Drizly, a privately held booze delivery app, seeing a 300% uptick in sales from earlier in the year. Publicly traded companies that are capitalizing on the massive expansion in mobile booze delivery include Uber Eats.

This quarantine is conditioning people to start using technology for all their needs, and I expect these delivery services to continue driving their toplines even after the quarantine has lifted.

Virtual Happy Hour

Bar closures and social distancing has been inspiring a new way to drink without feeling like a lonely alcoholic: virtual happy hour. For those of you unfamiliar, a virtual happy hour is when everyone grabs their drink of choice and jumps on a video conference call, allowing people to enjoy a drink in a (virtual) social setting while maintaining a safe physical distance.

This responsible social bonding is only made possible by video conferencing technologies like Zoom and Skype.

Alcohol Stocks

Alcohol stocks have been punished unjustly during this recent downturn with alcohol equities having tumbled roughly 34% since the beginning of the year, underperforming the S&P 500 by 15 percentage points.

Liquor stores have been qualified as essential businesses because they are such big money makers for the government. Alcohol sales should at least maintain if not grow during this quarantine.

There is a positive correlation between alcohol sales and unemployment rates (as depressing as that may sound). With unemployment figures expected to spike in the coming months, I suspect that the alcohol companies will see a boost in revenues.

My alcohol stock pick is Constellation Brands, despite their ownership of the recently infamous Corona beer. STZ has a broad portfolio of iconic beers, wines, and spirits that have driven topline growth for 8 consecutive years. The firm is producing strong-growing free-cash-flows giving the company flexibility to invest in long-term organic growth.

Constellations is hedging its bets with its partial ownership of Canadian marijuana company, Canopy Growth. This hedge has been working against STZ thus far, with CGC having plummeted in value over the past year. Still, I am confident that this long-term investment will pay-off once the industry progressively gains traction in Canada and is federally legalized in the US.

STZ has fallen over 22% since the beginning of the year, to its lowest price in over 3 years. STZ is now trading 23% below its average price target. I believe that this recent market turndown has allowed investors to buy this alcohol all-star at a discount.

Take Away

Remember that these are very rocky market waters, and volatility is expected to remain high until this pandemic can be controlled. There is an opportunity in alcohol sales and delivery, but I wouldn’t put on any substantial equity positions at the moment. The best strategy during times like these is to average down when the market breaks.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339               

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit information about the performance numbers displayed in this press release.